We are live on ! Find out more
Sector Gamma AS

Sector Gamma AS Portfolio holdings

AUM $485M Turnover 27.66%
1-Year Est. Return 34.91%
This Fund
S&P 500
This Quarter Est. Return
+9.01%
1 Year Est. Return
+34.91%
3 Year Est. Return
+61.8%
5 Year Est. Return
+76.8%
10 Year Est. Return
+241.56%
AUM
$485M
AUM Growth
+$24M
Cap. Flow
-$2.87M
Cap. Flow %
-0.59%
Top 10 Hldgs %
48.68%
Holding
47
New
7
Increased
10
Reduced
17
Closed
6
Avg Time Held
2.8 years
Top 10 Avg Time Held
2.3 years
Top 20 Avg Time Held
2.4 years

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$13M
2
BSX icon
Boston Scientific
BSX
+$8.66M
3
UNH icon
UnitedHealth
UNH
+$8.05M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$7.99M
5
AZN icon
AstraZeneca
AZN
+$7.51M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$16.8M
2
AMGN icon
Amgen
AMGN
+$9.5M
3
IQV icon
IQVIA
IQV
+$8.62M
4
BMY icon
Bristol-Myers Squibb
BMY
+$7.15M
5
DXCM icon
DexCom
DXCM
+$6.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
UNH icon
26
UnitedHealth
UNH
$296B
$7.34M 1.51%
+20,000
New +$8.05M
2026 Q3
0 quarters
AZN icon
27
AstraZeneca
AZN
$272B
$7.27M 1.5%
+45,049
New +$7.51M
2026 Q3
0 quarters
PTCT icon
28
PTC Therapeutics
PTCT
$4.87B
$7.26M 1.5%
112,000
+12,000
+12% +$874K
2024 Q4
7 quarters
IOVA icon
29
Iovance Biotherapeutics
IOVA
$3.38B
$5.76M 1.19%
388,466
-580,000
-60% -$4.15M
2026 Q1
2 quarters
EW icon
30
Edwards Lifesciences
EW
$60.5B
$5.21M 1.08%
60,402
– –
2022 Q4
15 quarters
KURA icon
31
Kura Oncology
KURA
$675M
$4.64M 0.96%
433,012
– –
2025 Q3
4 quarters
SNDX icon
32
Syndax Pharmaceuticals
SNDX
$822M
$4.54M 0.94%
241,739
– –
2025 Q3
4 quarters
TNDM icon
33
Tandem Diabetes Care
TNDM
$1.17B
$4.36M 0.9%
267,091
– –
2025 Q1
6 quarters
HCA icon
34
HCA Healthcare
HCA
$96.2B
$4.27M 0.88%
+10,000
New +$4.1M
2026 Q3
0 quarters
ASND icon
35
Ascendis Pharma
ASND
$16.8B
$4.17M 0.86%
18,305
-3,000
-14% -$760K
2025 Q1
6 quarters
TVTX icon
36
Travere Therapeutics
TVTX
$4.64B
$4M 0.83%
68,000
-12,000
-15% -$733K
2026 Q2
1 quarter
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$9.22B
$3.28M 0.68%
+6,500
New +$3.44M
2026 Q3
0 quarters
CYTK icon
38
Cytokinetics
CYTK
$7.17B
$2.97M 0.61%
45,000
– –
2026 Q2
1 quarter
DNLI icon
39
Denali Therapeutics
DNLI
$2.92B
$2.85M 0.59%
+137,718
New +$3.22M
2026 Q3
0 quarters
ARDX icon
40
Ardelyx
ARDX
$769M
$2.35M 0.48%
686,844
– –
2026 Q1
2 quarters
VRDN icon
41
Viridian Therapeutics
VRDN
$3.57B
$1.75M 0.36%
+84,867
New +$1.81M
2026 Q3
0 quarters
AMGN icon
42
Amgen
AMGN
$237B
– –
-26,281
Closed -$9.5M –
CRNX icon
43
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-114,628
Closed -$4.29M –
DXCM icon
44
DexCom
DXCM
$30.8B
– –
-102,122
Closed -$6.88M –
NTLA icon
45
Intellia Therapeutics
NTLA
$1.34B
– –
-185,177
Closed -$3.13M –
OGN icon
46
Organon & Co
OGN
$3.65B
– –
-270,781
Closed -$3.67M –
TMO icon
47
Thermo Fisher Scientific
TMO
$257B
– –
-33,584
Closed -$16.8M –

Similar funds

Sector Gamma AS's Q3 2026 Portfolio in Review

As of Q3 2026, Sector Gamma AS held 47 positions worth $485M, up 5.2% from $461M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sector Gamma AS's Q3 2026 filing shows 7 new, 10 increased, 17 reduced and 6 closed positions. Its largest new stake was Danaher: 63,381 shares worth $14M. The largest sale was Thermo Fisher Scientific, an estimated $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sector Gamma AS's largest Q3 2026 buy was Danaher: 63,381 shares worth $14M.
  • Sector Gamma AS added most to Boston Scientific in Q3 2026, an estimated $8.66M increase.
  • Sector Gamma AS's biggest Q3 2026 reduction was IQVIA, cutting an estimated $8.62M.
  • Sector Gamma AS fully exited Thermo Fisher Scientific in Q3 2026, selling an estimated $16.8M.
  • Sector Gamma AS's ten largest holdings make up 49% of its $485M portfolio in Q3 2026.
  • Sector Gamma AS opened 7 new positions and closed 6 in Q3 2026.
  • Sector Gamma AS's portfolio value rose 5.2% quarter-over-quarter to $485M.

Based on Sector Gamma AS's 13F filing for Q3 2026, filed 12 Nov 2026.